SCHEMBL8698703

SCHEMBL8698703

c1ccc(-c2ccccc2-c2nnnn2C(c2ccccc2)(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
AGTR1 P30556 1/20 0.47
AGTR2 P50052 1/20 0.47
ALDH1A1 P00352 6/20 0.38
TSHR P16473 3/20 0.38
ABCG2 Q9UNQ0 1/20 0.38
POLB P06746 2/20 0.37
HTT P42858 1/20 0.37
LMNA P02545 1/20 0.37
HSD17B10 Q99714 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
KMT2A Q03164 1/20 0.36
AGT P01019 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KCNN4 O15554 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL635 0.91 AGTR1 (0.51) AGTR1AGTR2ALDH1A1TSHRPOLB
SCHEMBL30956037 0.91 AGTR1 (0.51) AGTR1AGTR2ALDH1A1TSHRPOLB
SCHEMBL6532773 0.90 AGTR1 (0.46) AGTR1AGTR2ALDH1A1TSHRABCG2
SCHEMBL9383185 0.90 AGTR1 (0.46) AGTR1AGTR2ALDH1A1TSHRABCG2
SCHEMBL976147 0.88 LMNA (0.47) AGTR1AGTR2ALDH1A1TSHRPOLB
SCHEMBL30316147 0.87 AGTR1 (0.51) AGTR1AGTR2TSHRAGTKCNN4
SCHEMBL2053236 0.87 AGTR1 (0.44) AGTR1AGTR2ALDH1A1TSHRPOLB
SCHEMBL9024777 0.87 AGTR1 (0.51) AGTR1AGTR2TSHRAGTKCNN4
SCHEMBL8246839 0.86 AGTR1 (0.50) AGTR1AGTR2ALDH1A1POLBHTT
SCHEMBL9262004 0.86 AGTR1 (0.46) AGTR1AGTR2ALDH1A1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115583940-A Method for preparing losartan potassium key intermediate 润都制药(荆门)有限公司 2023-01-10 CN claimed
WO-2013072924-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTS AND INTERMEDIATES THEREOF. ALKEM LABORATORIES LTD. (IN) 2013-05-23 WO claimed
CN-115583940-A Method for preparing losartan potassium key intermediate 润都制药(荆门)有限公司 2023-01-10 CN disclosed
CN-115583940-A Method for preparing losartan potassium key intermediate 润都制药(荆门)有限公司 2023-01-10 CN disclosed
WO-2013072924-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTS AND INTERMEDIATES THEREOF. ALKEM LABORATORIES LTD. (IN) 2013-05-23 WO disclosed
CN-101481374-B Method for removing trityl group of 1-trityl-5-(1,1'-biphenylyl-2 yl)-1H-tetrazole compound ZHEJIANG HUAHAI PHARM CO LTD 2013-01-09 CN disclosed
CN-101481374-B Method for removing trityl group of 1-trityl-5-(1,1'-biphenylyl-2 yl)-1H-tetrazole compound ZHEJIANG HUAHAI PHARM CO LTD 2013-01-09 CN disclosed
CN-101481374-A Method for removing trityl group of 1-trityl-5-(1,1'-biphenylyl-2 yl)-1H-tetrazole compound ZHEJIANG HUAHAI PHARM CO LTD (CN) 2009-07-15 CN disclosed
CN-101481374-A Method for removing trityl group of 1-trityl-5-(1,1'-biphenylyl-2 yl)-1H-tetrazole compound ZHEJIANG HUAHAI PHARM CO LTD (CN) 2009-07-15 CN disclosed
US-5726319-A Biphenyl substituted dipeptide analogs promote release of growth hormone MERCK & CO., INC. (US) 1998-03-10 US disclosed
EP-0392317-A2 Benzimidazoles, drugs containing these compounds and process for their preparation Dr. Karl Thomae GmbH (DE) 1990-10-17 EP disclosed